urokinase-type plasminogen activator; thrombin; fibrinogen; shunt flow; aerosolization; ventilation-perfusion ratio ALVEOLAR FIBRIN FORMATION is a hallmark of many inflammatory lung diseases including acute respiratory distress syndrome (ARDS) (13, 16) . Under these conditions, both a manyfold increased leakage of plasma proteins, including fibrinogen, across a leaky endothelial and epithelial barrier and a pronounced shift of the alveolar hemostatic balance toward the procoagulative side have been documented (1, 10, 15, 16) . Alveolar protein levels may be elevated Ͼ10-fold in ARDS lungs, and the procoagulant activity, attributable to tissue factor and factor VII, was noted to be increased by approximately two orders of magnitude in severe ARDS and pneumonia. Both alveolar macrophages and epithelial cells have been shown to express and shed tissue factor into the alveolar lining layer in response to inflammatory stimuli (3, 14) . Moreover, alveolar levels of the urokinase-type plasminogen activator (uPA), the predominant plasminogen activator of the bronchoalveolar compartment, were found to be depressed in ARDS lungs (1, 10, 16) , whereas plasminogen activator inhibitor-1 levels were highly increased under these conditions (4, 15, 21) . Both fibrinogen leakage and these alterations in the alveolar hemostatic balance may thus be assumed to underlie alveolar fibrin formation in ARDS and other acute inflammatory lung diseases.
Pulmonary surfactant is a lipoprotein complex covering the alveolar surface and reducing the alveolar surface tension to near zero values at end expiration. Thereby, atelectasis during end expiration is prevented, and breathing is made feasible under regular transthoracic pressures. Impaired surface activity, with minimum surface tension values of Ն20 mN/m, has consistently been observed in surfactant isolates from patients with ARDS (6, 10, 11) or severe pneumonia, necessitating mechanical ventilation (10) . These changes have been ascribed to a variety of biochemical alterations, including changes in the phospholipid, fatty acid, and surfactant apoprotein profiles. In addition, inhibition of surfactant function by plasma proteins leaked into the alveolar space has been established as a powerful surfactant-inhibitory mechanism (10) . An in vitro study (28) documented the surfactantinhibitory capacity to be fibrinogen Ͼ hemoglobin Ͼ albumin. Moreover, the generation of a fibrin clot from fibrinogen in the presence of pulmonary surfactant was shown to cause the most severe surfactant inhibition in another in vitro study (27) . Compared with (soluble) fibrinogen, the dose-inhibition curve of fibrin is shifted to the left by more than two orders of magnitude. The incorporation of hydrophobic surfactant compounds into the nascent fibrin matrix, with a concomitant severe loss of surface tension-lowering properties, has been suggested as the underlying mechanism. Interestingly, in vitro proteolysis of surfactant-incorporating fibrin clots was shown to be suitable for "rescue" of the surfactant material trapped in the fibrin matrix (8) , with its surface tension-lowering properties being conserved.
The present study employed aerosol techniques for sequential alveolar delivery of fibrinogen and thrombin in intact rabbit lungs to create a model of selective alveolar fibrin formation. Marked deterioration of ventilation-perfusion (V A/Q ) matching with a predominance of shunt flow, reminiscent of gas exchange disturbances in ARDS, occurred under these conditions, with changes far surpassing those of sole fibrinogen challenge. Rescue inhalation of either urokinase or surfactant, undertaken after formation of the alveolar fibrin clots, reduced the gas exchange abnormalities, but by far the most effective approach for restoration of gas exchange properties was the combined rescue administration of surfactant and urokinase. Targeting alveolar fibrin formation by transbronchial administration of surfactant plus urokinase might thus offer a new therapeutic strategy in acute inflammatory lung diseases with extensive hyaline membrane formation, thereby further expanding current strategies of transbronchial surfactant administration in patients with severe ARDS (7, 32) .
METHODS

Materials.
The mouse monoclonal anti-human D-dimer antibody (murine IgG3 clone DD-3B6/22) was purchased from American Diagnostic (Greenwich, CT). The antibody recognizes D-dimer and cross-linked fibrin derivatives (DD-E) and shows no reactivity with human fibrinogen or fibrinogen degradation products. Bovine serum albumin (BSA-C) and silver-enhancer solution were purchased from Biotrend (Cologne, Germany). Human uPA (Actosolv; specific activity 120,000 U/mg protein), thrombin (specific activity 1,250 U/mg protein), and fibrinogen (Haemocomplettan) were from Behring (Marburg, Germany). Bovine surfactant was a gift from Dr. Karl Thomae (Alveofact, Boehringer Ingelheim, Biberach an der Riss, Germany).
Isolated lung model. The perfused lung model has been previously described in detail (29) . Briefly, rabbits were deeply anesthetized and anticoagulated with heparin (1,000 U/kg). After a tracheostomy, the animals were ventilated with room air. After a midsternal thoracotomy, catheters were placed into the pulmonary artery and left atrium, and perfusion with Krebs-Henseleit buffer was started. The lungs were perfused (total volume 400 ml) with a flow of 150 ml/min. Left atrial pressure was set at 1.0 mmHg in all experiments. In parallel with the onset of artificial perfusion, room air supplemented with 5% CO 2 was used for ventilation (volume-controlled, positive end-expiratory pressure 1 cmH 2 O). The isolated lungs were then ventilated and perfused for a steady-state period lasting 30 min. Lungs that displayed visible signs of infection, gained Ͼ2 g of weight during the steady state, or showed an increase in pulmonary arterial pressure (Ppa) were excluded from the further course of the study.
Gravimetric estimation of the capillary filtration coefficient. The capillary filtration coefficient (K fc ) was determined gravimetrically, employing a sudden venous pressure elevation of 10 cmH 2 O for 8 min. K fc was calculated by time (t) 0 extrapolation of the slope of the weight gain with a semilogarithmic plot of the rate of weight gain of the lung according to Taylor and Gaar (30) . Vascular compliance was determined as the change in vascular volume per change in microvascular pressure. The initial rapid change in weight over the first 2 min was used for the calculation of vascular compliance (30) . Retention weight was defined as the difference in weight gain before and after venous pressure elevation.
Aerosol procedures. Aerosolization of isotonic saline, human uPA, human fibrinogen (15 mg/ml), and a calf lung surfactant extract (15 mg/ml) was performed by means of an ultrasonic nebulizer (Pulmo Sonic 5500, DeVilbiss Medizinische Produkte, Langen, Germany). This device produces an aerosol with a mass median aerodynamic diameter of 4.5 m and a geometric standard deviation of 2.1 as measured with a laser diffractometer (HELOS, Sympatec, ClausthalZellerfeld, Germany). Bovine thrombin was aerosolized with another ultrasonic nebulizer (Portasonic II, DeVilbiss Medizinische Produkte), with a mass median aerodynamic diameter of 4.3 m and a geometric standard deviation of 2.2. The nebulizers were connected to the inspiratory tubing of the ventilation system. Condensation of aerosolized material within the inspiratory limb of the ventilation system was reduced by heating to 40°C. Under these conditions, a lung deposition rate of 25% of the initially generated aerosol mass was achieved (25) . This deposition fraction, which was controlled periodically, was taken into consideration when calculating the quantity of agents delivered to the bronchoalveolar space by aerosolization. The total nebulized dose was obtained by weighing the nebulizer before and after the aerosolization maneuvers. In a preceding study (25) , ultrasonic nebulization was ascertained not to impair the biophysical and biochemical properties of surfactant material. Similarly, the clotting ability of the fibrinogen preparation used in the present study was found to be unaffected by the aerosolization procedure (Ͼ95% clot formation both pre-and postnebulization). In contrast, the specific activities of uPA and thrombin were found to be reduced to 89 and 73%, respectively, of the initially provided activity (measured in vitro by aerosol trapping and subsequent measurement of activity by means of the chromogenic substrates S-2444 and S-2238). All data concerning the total deposited pulmonary activity of thrombin and urokinase were corrected for this loss of activity during the nebulization procedure.
V A/Q determination in isolated lungs by multiple inert gas elimination technique. The continuous V A/Q distributions were determined by the multiple inert gas elimination technique (MIGET) as described by Wagner and West (31) . Determination of V A/Q distribution was performed by least squares analysis. An indication of the acceptable quality of the V A/Q distributions is a residual sum of squares of 5.348 or less in half of the experimental runs (50th percentile) or 10.645 or less in 90% of the experimental runs (90th percentile) (31) . In the present study, 72.4% of the residual sum of squares were Ͻ5.348 and 98.4% were Ͻ10.645.
Experimental protocol. Seven experimental groups were employed. The treatment protocol of six groups is shown in Fig. 1 . At the end of the steady-state period, a baseline V A/Q measurement was performed and time was set at zero. Nebulization of the different agents was then undertaken from t ϭ 0 until t ϭ 60 min, from t ϭ 65 until t ϭ 75 min, and from t ϭ 95 until t ϭ 155 min. Additional MIGET analysis was performed at 90, 165, and 195 min. The control group re-ceived nebulized saline to ensure equivalent fluid load of the lungs. In the fibrinogen (Fbg) group, aerosolization of fibrinogen was combined with two saline nebulization periods, resulting in a total fluid loading of 7.4 g as measured for this group. In the fibrin (Fbg-Thr) group, fibrinogen was aerosolized with subsequent nebulization of thrombin to induce fibrin formation. Total lung fluid deposition was 8.6 g. Rescue applications were undertaken after the preceding fibrin formation, with the timing and dose of these rescue applications shown in Fig. 1 . The protocols included the administration of surfactant (Fbg-Thr-Surf group), uPA (Fbg-Thr-uPA group), and a combination of these agents (Fbg-Thr-Surf-uPA group). The total lung fluid load measured in these experiments was 7.0, 7.4, and 7.3 g, respectively.
In a separate set of experiments, vascular permeability and gas exchange in response to high doses of inhaled urokinase and thrombin (n ϭ 4 experiments/group) was investigated in control lungs. Three doses of inhaled uPA and one dose of inhaled thrombin were employed. Measurements of K fc and V A/Q were performed after termination of the steadystate period (t ϭ 0) and were repeated after 70 and 120 min. Nebulization of uPA was performed from t ϭ 10 until t ϭ 70 min with three doses: 4,111 Ϯ 564 U/kg body wt (dose 1), 6,106 Ϯ 889 U/kg body wt (dose 2), and 10,227 Ϯ 2,031 U/kg body wt (dose 3). Thrombin was nebulized from t ϭ 10 until t ϭ 20 min (9.4 Ϯ 1.2 U/kg body wt).
Bronchoalveolar lavage. Bronchoalveolar lavage (BAL) was performed at the end of each experiment. For this purpose, a total volume of 50 ml of saline was instilled and reaspirated three times, and the recovered fluid was filtered through sterile gauze. Cells were removed by centrifugation at 300 g for 10 min, and the cell-free supernatant was divided into aliquots and stored at Ϫ80°C until further processing.
Quantification of D-dimer. D-dimer was measured by a commercially available ELISA kit (Boehringer Mannheim, Mannheim, Germany). The assay was performed as recommended by the supplier.
Immunohistochemistry and microscopy. Fixation was performed by overnight immersion of the lungs in a 3% paraformaldehyde solution (n ϭ 3 lungs). For paraffin embedding, whole lungs were dissected in tissue blocks from all lobes. Sectioning at 10 m was performed from all paraffin-embedded blocks. Immunohistochemistry was performed as recently described in detail (5) . Briefly, paraffin sections were dewaxed, rehydrated, and preincubated in PBS containing 5% goat serum, 0.025% BSA-C, 0.05% Tween 20, and 0.02 M glycine to block unspecific binding. Overnight incubation with the monoclonal anti-human D-dimer antibody diluted 1:50 was carried out at 4°C. Incubation with secondary goldconjugated antibodies diluted 1:400 was performed overnight at 4°C. Next, the sections were fixed for 5 min in 2% phosphate-buffered glutaraldehyde and after several washes in glass double-distilled water, incubated in silver enhancer solution for 50 min. Counterstaining of the sections was performed with nuclear fast red. Control staining was performed by omission of the primary antibody or substitution with nonspecific preimmune serum at the same dilution.
Microscopy was performed with a Leica DM RXA microscope (Leica, Wetzlar, Germany) at a magnification of ϫ250. Epipolarization depiction of the immunogold-silver-stained structures created a complete segmentation between positively stained and nonstained tissue. Gray-scale images were digitized with a 12-bit cooled charge-coupled device camera (Sensys KAF 1400, Photometrics, Tucson, AZ) connected with the host computer. For direct visualization of staining intensity, a pseudocolor scale with 11 colors was chosen, each representing an equal sector of the intensity scale, and applied to the images.
Data analysis. All values are given as means Ϯ SE or as a coefficient of variation (SD/mean in percent). For analysis of statistical differences, two-tailed Student's t-test for unpaired samples was performed. After Bonferroni's correction, a P value Ͻ 0.05 was considered significant.
RESULTS
Baseline variable responses to the nebulization of saline. All lungs employed in the current study displayed Ppa values in the range between 6 and 9 mmHg and a mean K fc value of 5.2 ϫ 10 Ϫ5 Ϯ 1.2 ϫ 10
Ϫ1 at the end of the steady-state period. Baseline V A/Q measurements revealed a unimodal, narrow distribution of perfusion and ventilation to midrange V A/Q (0.1 Ͻ V A/Q Ͻ 10) areas throughout. Shunt flow (V A/Q Ͻ 0.005) and perfusate flow to poorly ventilated areas (low V A/Q areas; 0.005 Ͻ V A/Q Ͻ 0.1) were extremely low (Ͻ2.5%), and no perfusion of high V A/Q regions (10 Ͻ V A/Q Ͻ 100) was observed (data not shown in detail). Dead space ventilation (V A/Q Ͼ 100) approximated 50% of ventilation in this system of isolated lung ventilation. These data correspond to previous investigations in the perfused rabbit lung (29) and document a physiological V A/Q distribution and an intact endothelial and/or epithelial barrier in these isolated organs.
Nebulization of isotonic saline (control), which was performed to mimic the total fluid burden and to characterize the effect exerted by this volume load per se, did not affect Ppa, ventilation pressure (Table 1) , or K fc values (data not shown in detail). A total weight gain of 7.9 g was monitored, being equivalent to the total deposited aerosol mass (8.3 g). After 155 min, there was a small but nonsignificant increase in perfusate flow to low V A/Q areas (maximum 2.3%; see Table 1 ) and in shunt flow (maximum 3.8%) as well as a concomitant very minor decrease in the perfusion of areas with normal V A/Q ratios.
Vascular permeability and gas exchange in response to inhaled uPA and thrombin. Nebulization of 9.4 U/kg body wt of thrombin did not affect Ppa, weight gain, ventilation pressure (Table 2) , or lung gas exchange (data not shown in detail). K fc , vascular compliance, and retention (weight gain during venous pressure challenge) remained unchanged (Table 2) . Similarly, lung deposition of 4,111 Ϯ 564 U uPA/kg body wt did not alter K fc , vascular compliance, retention, and Ppa (Table 2) . However, when uPA doses of 6,106 Ϯ 889 and 10,227 Ϯ 2,031 U/kg body wt were provided to the alveolar compartment, significant increases in K fc values up to 11.9 ϫ 10 Ϫ5 Ϯ 3.6 ϫ 10 Ϫ5 and 22.2 ϫ 10 Ϫ5 Ϯ 2.9 ϫ 10
, respectively, were noted ( Table 2 ). The highest uPA dose also caused a marked increase in fluid retention (weight gain) during the venous challenge maneuver. Ppa, vascular compliance, and ventilation pressure remained unchanged.
Effects of fibrinogen deposition and fibrin formation in the alveolar compartment. Aerosolization of fibrinogen resulted in a moderate increase in shunt flow from 1.2 Ϯ 0.3 to 7.4 Ϯ 2.1% and a slight increase in perfusion to poorly ventilated areas to 1.3 Ϯ 1.1% (Table 1) . Dead space ventilation increased by ϳ5%. Ppa remained constant (7.2 Ϯ 0.4 mmHg at 0 min and 7.4 Ϯ 0.4 mmHg at 195 min), whereas lung weight displayed a progressive increase, resulting in a total Values are means Ϯ SE. V A/Q , ventilation-perfusion; Fbg, fibrinogen; Thr, thrombin; Surf, surfactant; uPA, urokinase-type plasminogen activator; low V A/Q , perfusion of areas with 0.005 Ͻ V A/Q Ͻ 0.1; log SD Q , log SD of perfusion; dead space ventilation, ventilation of areas with V A/Q Ͼ 100. Significant difference from control: * P Ͻ 0.05; † P Ͻ 0.01. weight gain of 10.7 Ϯ 1.8 g at the end of the experiments. As in the control group, the major part of this weight gain was, however, due to the total deposited aerosol mass of 7.4 g. Induction of fibrin formation by sequential aerosol application of fibrinogen and thrombin caused severe deterioration of V A/Q matching, with a progressive increase in shunt flow to 22.4 Ϯ 1.4% (Fig. 2) and some additional perfusion of poorly ventilated areas (4.5 Ϯ 1.4%; Table 1 ). Dead space ventilation increased significantly from 44.9 Ϯ 2.6 to 60.2 Ϯ 1.6% of total ventilation, and a broadening of the perfusion distribution in the midrange V A/Q areas occurred, indicated by an increased log SD of perfusion (log SD Q ; Table 1 ). Ppa remained unaltered, whereas weight gain increased to 12.5 Ϯ 1.3 g (8.6 g of deposited aerosol) at the end of the experiments. In addition, some moderate increase in ventilation pressure was noted (Table 1) .
Fibrin was detected by immunohistochemistry and was found predominantly in the alveolar compartment (Fig. 4) . Some minor deposition in the conducting airways was noted, however, without airway occlusion. Distribution among the different regions of the lung was rather homogeneous, and image analysis also revealed a homogeneous distribution of staining intensity within the alveolar spaces.
Rescue administration of surfactant and/or uPA. In lungs with preceding fibrin formation due to the combined application of fibrinogen and thrombin, aerosol application of surfactant resulted in a significant decrease in shunt flow to 12.1 Ϯ 2.7%. The percentage of perfusion of low V A/Q areas was largely unchanged by this intervention (5.4 Ϯ 3.2%; Table 1 ). Perfusion of normal V A/Q areas was thus increased compared with that in the Fbg-Thr group (Fig. 3) . Dead space ventilation was 63.4% at the end of the experiments. V A/Q mismatch, indicated by log SD Q , was reduced compared with that in the Fbg-Thr group (Table 1) . Ppa was not altered by this intervention. Total lung weight gain was 18.2 Ϯ 1.8 g at the end of the experiments (7 g of deposited fluid volume) in the Fbg-Thr-Surf group, and some increase in ventilation pressure occurred.
Aerosol application of 4,588 U/kg body wt of uPA subsequent to alveolar fibrin formation resulted in a moderate reduction in pulmonary shunt flow (17.5% at the end of the experiments), which was not significantly different from that in the Fbg-Thr group (Fig. 2) . Perfusion of low V A/Q areas was reduced (3.6%; Table  1 ), and that of normal V A/Q areas was increased (Fig.  3) . The broadening of perfusion distribution in midrange V A/Q areas (log SD Q ) was not different from that in the Fbg-Thr group (Table 1) . At the end of the experiments, dead space ventilation was 60% and Ppa was 9.7 mmHg. Total weight gain at this time was 18.9 g (7.4 g of deposited fluid), and peak ventilation pressure increased to a mean of 10.2 mmHg. Values are means Ϯ SE. K fc , capillary filtration coefficient; retention, weight gain induced by the maneuver of venous pressure elevation for determination of K fc . Thrombin, 9.4 U/kg body wt; uPA dose I, 4,111 Ϯ 564 U/kg body wt; uPA dose II, 6,106 Ϯ 889 U/kg body wt; uPA dose III, 10,227 Ϯ 2,031 U/kg body wt. Significant difference from time 0 measurement: * P Ͻ 0.05; † P Ͻ 0.01. Combined aerosol application of uPA and surfactant resulted in a highly significant decrease in intrapulmonary shunt flow (Fig. 2 ) to 6.8% at the end of the experiments. Notably, this regimen was the only one that not only inhibited the further increase in shunt flow but also reversed the extent of shunt flow, which already represented Ϸ12% after termination of alveolar fibrin formation in this group. Similarly, perfusion of low V A/Q areas was reduced to 2.4% at the end of the experiments ( Table 1) . As a result, perfusion of normal V A/Q areas was markedly increased and approached the data with fibrinogen application alone (Fig. 3) . Dead space ventilation was 57.8% in this group at the end of the study, and total weight gain was 14.0 g, with half of this weight gain (7.3 g) resulting from the nebulization maneuvers per se. As detailed in Table 1 , Ppa and ventilation pressure were not substantially influenced by the rescue administration of surfactant and uPA.
BAL fluid analysis. Measurement of the BAL fluid D-dimer levels showed very low concentrations of this scission product of cross-linked fibrin in the control and fibrinogen-treated lungs (Fig. 5) . Subsequent to alveolar fibrin formation due to additional thrombin aerosolization (Fbg-Thr group), the BAL fluid D-dimer content increased significantly, and this also held true for the surfactant-treated (Fbg-Thr-Surf) group. The highest D-dimer levels in the BAL fluid were encountered in the two uPA treatment (Fbg-Thr-uPA and Fbg-ThrSurf-uPA) groups.
DISCUSSION
The present study was performed in a model of bufferperfused, ventilated rabbit lungs previously characterized in detail (29) . The advantages of this model are 1) control of pulmonary hemodynamics, continuous monitoring of lung weight, and repetitive assessment of the K fc , 2) the absence of bloodborne components that might possibly confound the effects caused by selective alveolar fibrin formation, and 3) the suitability to employ aerosol technology for alveolar drug delivery. In addition, MIGET, previously adapted to this isolated lung model (33) , offers a powerful tool to analyze gas exchange conditions in detail (23) . As documented by baseline measurements, hemodynamics, endothelial and/or epithelial barrier function, and V A/Q matching are well within the physiological range in these bufferperfused lungs.
In the control experiments, nebulization of saline was undertaken to mimic the extent of alveolar fluid deposition effected by the experimental protocols employing fibrinogen aerosolization. Interestingly, the net lung fluid loading of Ϸ8 g, assessed both by measurement of aerosolized mass and by monitoring of lung weight gain, did not affect pulmonary hemodynamics, vascular integrity, and ventilation pressure at all. Moreover, physiological V A/Q matching was virtually fully maintained, with only minimal shunt flow (Ϸ3%) noted at the end of the experiments. Thus alveolar fluid deposition per se, resulting in an approximate doubling of the baseline lung weight, is apparently well tolerated with respect to gas exchange in these intact lungs.
Alveolar deposition of a fibrinogen solution, again causing an ϳ8-g net lung weight, provoked an increase in shunt flow to Ϸ7% along with a very minor increase in perfusion of low V A/Q areas and a corresponding decrease in perfusion of normal V A/Q regions. This finding is very compatible with an in vitro study (28) that demonstrated the surfactant-inhibitory capacities of fibrinogen. When the ratio of aerosolized fibrinogen (ϳ20 mg/kg body wt) to the endogenous rabbit alveolar surfactant pool [ϳ7 mg/kg (25) ] is calculated, some moderate inhibition of surfactant function is to be anticipated from the in vitro studies, and this might well cause some limited extent of atelectasis and shunt flow.
In vitro studies addressing the surfactant-inhibitory capacity of proteins also forwarded the concept that hydrophobic surfactant components, phospholipids, and the surfactant apoproteins B and C are incorporated into a nascent fibrin matrix and that nearly complete incorporation of these surfactant constituents, with severe inhibition of surface activity, already occurs at a fibrin-to-surfactant ratio of 1:5 (27) . This study is the first one to rigorously test this concept in intact lungs by sequential aerosolization of fibrinogen and thrombin, the latter being applied at a dose that per se does not induce pulmonary abnormalities. With this approach, the generation of up to ϳ20 mg/kg body wt of fibrin was to be anticipated, and the appearance of alveolar fibrin deposits, very much resembling hyaline membrane formation, was nicely demonstrated by the immunohistological studies. Indeed, a marked progressive shunt flow, surpassing 20% at the end of the experiments, as well as perfusion of low V A/Q areas (4-5%) was noted in these lungs, indicating severe surfactant deterioration, with a loss of alveolar patency in the fibrin-loaded lungs. Concomitantly, the perfusion of normal V A/Q areas was significantly decreased. Thus fibrin generation in the alveolar compartment is apparently a potent surfactant-inhibitory mechanism, with a severe impact on gas exchange under conditions of intact lung architecture. This finding also supports previous investigations (22, 24, 25) employing different surfactant-inhibitory interventions in intact lungs (e.g., lavage, detergents, acid aspiration) in which a deterioration of V A/Q matching with a predominance of shunt flow was consistently demonstrated.
In several of these previously reported models of surfactant inhibition (18-20, 24, 25) , transbronchial administration of exogenous surfactant either by instillation or by aerosolization was found to improve gas exchange and, in particular, to reduce shunt flow, compatible with restoration of alveolar surfactant function. Even when applied as an aerosol, surfactant might reach atelectatic lung regions due to its adsorption and lateral spreading facilities. It is in line with these observations that a significant improvement in gas exchange was noted in response to surfactant nebulization, undertaken subsequent to the current protocol of alveolar fibrin formation. The presently deposited surfactant quantity of Ϸ15 mg/kg body wt is well in line with previous experimental surfactant replacement strategies employing aerosol technology (12, 18, 20, 24, 25) . However, the overall efficacy of the transbronchial surfactant administration was somewhat limited in the present study in fibrin-loaded lungs compared with that in lavage models (18, 20, 24) . The most reasonable explanation for this finding is the assumption that the presence of fibrin interferes with the entrance of surfactant into the alveolar spaces or that even strong apposition of alveolar walls ("fibrin gluing") may occur.
To target alveolar fibrin formation more directly, nebulization of urokinase was undertaken as a rescue regimen. When this approach was tested in preceding pilot experiments, the pulmonary deposition of ϳ10,000 U/kg body wt of uPA was found to significantly increase the K fc , which may be due to the lysis of extracellular matrix components, with subsequent enhanced fluid flux under conditions of an increased pulmonary venous pressure challenge. In contrast, pul- monary deposition of ϳ4,500 U/kg body wt of urokinase did not exert any effect on lung barrier properties, ventilation pressure, and pulmonary hemodynamics. This dose appears to be low compared with the uPA doses currently used in acute myocardial infarction, where 40,000-50,000 U/kg body wt may be employed (26) . It has to be kept in mind, however, that the volume of the bronchoalveolar lining layer, to which the nebulized urokinase is first distributed, is lower by many orders of magnitude than the circulating blood volume, even under conditions of lung edema formation. Moreover, measurement of the perfusate levels of urokinase did not detect rapid passage of the aerosolized protease into the intravascular space (ELISA technique; data not shown). The efficacy of nebulized urokinase to cause fibrin lysis in the alveolar space is documented by the increase in lavage fluid D-dimer levels in response to this regimen. It is known from an in vitro study (8) that a urokinase attack on surfactantincorporating fibrin is capable of liberating functionally intact surfactant, which might then be assumed to improve surface tension properties at the alveolar surface. Indeed, some retardation of shunt flow development and perfusion of low V A/Q areas was noted in the urokinase-treated lungs; however, the data did not significantly differ from the values in nontreated lungs. Thus, although showing some efficacy, the presently employed dose of urokinase, designed to avoid induction of lung permeability increase by this protease, resulted only in a minor improvement of gas exchange in the fibrin-loaded lungs.
Most interestingly, the combined aerosol administration of urokinase and surfactant turned out to be the most effective approach for improvement of V A/Q matching in the present model of alveolar fibrin deposition. Notably, not only retardation of shunt development but reversal of the extent of shunt flow was achieved by this approach, with percentages of shunt at the end of the experiments being in the same range as in the lungs undergoing fibrinogen-alone administration (Ϸ7%). In addition, low numbers of low V A/Q areas were noted, thus resulting in a markedly increased flow to lung units with normal V A/Q ratios. Thus one very plausible explanation might be that the surfactant facilitated the distribution of urokinase to the fibrin-loaded alveolar spaces (surfactant as carrier), thereby enhancing the overall fibrinolytic efficacy of the nebulized uPA and converting most fibrin into fibrin split products; the surfactant-inhibitory capacity of the split products only slightly surpasses that of fibrinogen. However, lavage fluid D-dimer levels were not found to be increased in the urokinase-surfactant group compared with the urokinase-alone group. Thus, as an alternative explanation, some limited urokinaseinduced fibrinolysis might allow better access of the exogenously administered surfactant material to the alveolar compartment, thereby enhancing the beneficial impact of the exogenous surfactant material on surface tension regulation and alveolar stability.
In conclusion, the present study demonstrates that alveolar fibrin formation, induced in an intact lung with otherwise physiological function, provokes severe gas exchange abnormalities, with a predominance of shunt flow. This finding is very compatible with the hypothesis that fibrin formation in the alveolar compartment is a potent inhibitor of surfactant function, resulting in a loss of alveolar stability. Rescue administration of surfactant and urokinase, both aerosolized after formation of the fibrin deposits, reduced the progressive development of shunt flow in this model, with surfactant being more potent. The most efficient approach, however, was the conebulization of surfactant and urokinase, which reversed shunt flow and markedly increased perfusion of normal V A/Q areas. Clearly, it has to be kept in mind that these results were obtained in an in vitro model, not under in vivo conditions of acute respiratory failure. However, the proof of the concept (high efficacy of conebulization of surfactant and urokinase) was beyond doubt documented in this model. Thus combined surfactant and urokinase administration may indeed offer a new therapeutic regimen in conditions with marked and persisting alveolar fibrin formation such as severe or delayed ARDS and pneumonia demanding mechanical ventilation (9, 16) and rapidly progressive idiopathic lung fibrosis (3, 17) , in which each agent alone might not have easy access to the fibrin-filled alveolar spaces. The currently employed dose of urokinase was chosen to avoid induction of vascular leakage, but further studies in intact animal models will be mandatory to figure out whether coaerosolization of surfactant and a fibrinolytic agent may be operative without provoking lung bleeding. Beyond the present target variable (restoration of gas exchange), this approach may also be of interest in view of the hypothesis that delayed clearance of fibrin in inflammatory lung diseases may favor the progression into lung fibrosis, with surfactant-depleted and fibrin-glued alveolar spaces serving as nidi for fibroblast invasion (concept of collapse induration) (2) .
